Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor‐tyrosine kinase inhibitor therapy

BACKGROUND: Epidermal growth factor receptor (EGFR) gene mutations predict tumor response to EGFR tyrosine kinase inhibitors (EGFR‐TKIs) in non‐small cell lung cancer (NSCLC). However, even patients with EGFR‐sensitive mutations in NSCLC have limited efficacy with EGFR‐TKI. Studies have shown that l...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Thorac Cancer
Autors principals: Lv, Panpan, Yang, Shaoxing, Liu, Wenjing, Qin, Haifeng, Tang, Xiuhua, Wu, Fangfang, Liu, Zeyuan, Gao, Hongjun, Liu, Xiaoqing
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons Australia, Ltd 2019
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6938758/
https://ncbi.nlm.nih.gov/pubmed/31691525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13216
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars